CRL vs. KYMR: Charles River Laboratories vs. Kymera Therapeutics Stock Comparison

Company Profile

Charles River Laboratories (CRL) and Kymera Therapeutics (KYMR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while KYMR is classified in Biotechnology.

Charles River Laboratories (CRL) has more than two decades of public-market history since June 23, 2000, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Charles River Laboratories (CRL) reports 1.27%, ranking against industry peers normally.

Both Charles River Laboratories (CRL) at 1.01% and Kymera Therapeutics (KYMR) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Charles River Laboratories (CRL) reports 23.42%, ranking against industry peers normally.

Profitability Metrics

Growth

Both Charles River Laboratories (CRL) at -0.85% and Kymera Therapeutics (KYMR) at -16.70% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.

Kymera Therapeutics (KYMR) at 0.05 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Charles River Laboratories (CRL) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Charles River Laboratories (CRL) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Charles River Laboratories (CRL) at 4.07 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Charles River Laboratories (CRL) at 5.01 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

Valuation Metrics